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Abstract
Background: Cancer is a major cause of morbidity and mortality, among which ovarian cancer has a high incidence and case fatality.
Gaining insight into the epidemiology and trends of ovarian cancer can be very influential in cancer screening and treatments
programming. This study aimed to investigate the trends in the incidence of ovarian cancer in Iran, because this issue has been
neglected so far.
Methods: This study is a re-analysis of existing data from the cancer data recording system in Iran during the years 2003 to 2009.
The incidence rates reported were standardized according to the world health organization (WHO) and the trend in the incidence
of this disease was determined by STATA software and the significance of the morbidity trend diagram was also derived via WINPEPI
software.
Results: The statistics of cancer registry center shows an increasing trend of ovarian cancer from 2003 to 2008, while it decreased
from 2008 to 2009. During this period, 6078 cases of ovarian cancer were registered in Iran, increasing from 591 cases in 2003 to 1077
in 2009, which shows an approximately 2-fold increase in the incidence of registered cases. During these seven years, the highest
incidence rate was seen in Markazi province with 6.33 per 100,000 persons and the least in Kohkiloye-va-Boyerahmad province with
zero incidence. Almost all provinces, except a few, had increasing incidence of ovarian cancer.
Conclusions: According to the results of the study, the incidence of ovarian cancer is increasing in Iran, especially in the central
and northwestern regions of the country. This increase may be due to changing the patterns of risk factors for this disease, such as
changes in lifestyle in the population, which will lead to changes in the incidence of the disease. Hence, due to the increase in inci-
dence of this cancer, it is recommended to implement screening and early detection programs in high risk areas and populations.
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1. Background
Cancer is one of the three main causes of death around
the world (1). The death rate from cancer was 8,200,000
in 2012, which has had a 4.8% increase since 2008 (1, 2). In
Iran, cancer is the third most prevalent cause of death. An-
nually, over 30,000 people lose their lives due to cancer in
Iran (3). It is estimated that each year more than 70,000
new cases of cancer occur in Iran and with increasing life
expectancy and the percentage of elderlies in the popu-
lation, it is expected that the incidence of cancer be dou-
bled in the next two decades (3, 4). Investigating the causes
of women’s mortality showed that cancers are the second
cause of death in women, and among gynecologic cancers,
ovarian cancer, is the fourth leading cause of mortality in
women (5). Gynecologic cancers are also the most com-
mon cause of death in women in North America, North-
ern Europe and Western Europe (1, 6, 7). The incidence
of this cancer varies from 9 to 17 new cases per 100,000
women per year (7, 8). Ovarian cancer has the highest mor-
tality rate among gynecologic cancers (9). The most com-
mon ovarian cancer is the epithelial type and usually about
60% of patients present with metastasis due to minimal
symptoms (10, 11). The mean age of women at diagnosis is
51 years (12). Although the improved treatment methods
of ovarian cancer has increased the life expectancy of pa-
tients in the last decade, patients’ survival has ultimately
increased slightly (13). One of the major causes of mortal-
ity in these patients, despite appropriate treatment, is de-
lay in referral of women with ovarian cancer, especially ep-
ithelial tumors (14). Therefore, measures should be imple-
mented in order to prevent the risk factors and identifica-
tion of symptoms to patients, so that the prevalence of the
disease and its complications decline. In particular, in the
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era of modern health care systems, where prevention in
the first level is the preferred method, compared to other
issues. Only 10% of tumors occur in women younger than
40 years and about 3% in women under 30 (15).
Currently, there is no approved method for screening
ovarian cancer, so efforts are conducted to identify early
symptoms of ovarian cancer with the hope that cancer can
be diagnosed and treated at an early stage (16, 17). If the
diagnosis in the first phase can reach from 25% to 75%, the
mortality rate of this disease will decrease by 50% (17). Sev-
eral factors are involved in the development of ovarian can-
cer, including reduced number of pregnancies, in addition
to infertility that increase the incidence of the disease (18).
Other important factors include the long reproductive pe-
riod, (early menarche, and late menopause) and history of
infertility (19). Obesity in adulthood can increase its preva-
lence up to 50% before menopause. On the other hand, hav-
ing at least one child or using oral contraceptives for more
than 5 years reduces the risk of ovarian cancer (20). The sur-
vival rate of the affected patients is placed after the survival
rates of the breast, lung and colon cancers; the 5-years’ rel-
ative survival of this cancer in general is reported from 30
to 50% in various reports, but at the same time, sufficient
studies have not been conducted in this regard in Iran (21).
2. Objectives
It seems that the prevalence of this disease is high in
Iran, but there is no study determining the trend of this
important disease and the changes in its incidence in re-
cent decades and its epidemiology in Iran; the few studies
are regional with limited samples and as far as epidemi-
ologic data is a prerequisite for successful planning, this
study aimed to assess the epidemiology and determine the
trends in the incidence of ovarian cancer in Iran from 2003
to 2009.
3. Methods
The present cross-sectional study was conducted us-
ing available data. The data from national cancer registry
and the center for disease control of the ministry of health
and medical education has been used. Center for Disease
Control receives data from pathology centers in the coun-
try, and controls them for accurate coding, information
deficits and duplications by Pars software. Population-
based cancer registries, by definition, use multiple sources
(including hospital records, records from diagnostic fa-
cilities and even death certificates) to collect cancer data.
While this is usually easier to achieve in smaller coun-
tries, a vast geographical territory such as Iran, with its cli-
mate and cultural diversity, may pose technical and logis-
tic problems to this objective. While the pathology-based
cancer registration is in place, we hope that the addition of
the population-based cancer registries, and establishment
of new registries in poorly covered areas, will improve can-
cer reporting in the country (22, 23). In this study, all
cases, registered since 2003 to 2009 in the whole country
as well as the statistics of ovarian cancer in all provinces,
have been studied. The direct incidence reported was then
standardized according to the world health organization
(WHO) standards. The collected data was accordingly in-
vestigated for the whole country based on the number of
cases and standardized incidence rates for provinces. Af-
ter data collection, the chart of the disease trend during
the study period and the prevalence of ovarian cancer were
drawn for different regions. The significance of figures was
calculated by using the WinPepi software.
4. Results
Assessing the statistics of cancer registry center in Iran
shows that from 2003 to 2009, the incidence of ovarian
cancer had an increasing trend in women since 2008;
while after 2008, it had a decreasing trend, compared to
the previous years (Figure 1). According to this statistics,
6078 cases of ovarian cancer were recorded during this pe-
riod. The highest number has been reported in 2008 with
1096 cases and the lowest in 2003 with 736 cases (Table
1). The statistics of cancer registry center showed that the
highest incidence in women’s cancer was in 2008 with 4.25
per 100,000 women and the lowest in 2003 with 34.2 per
100,000 people. Also, the survey of central cancer registry
showed the incidence of ovarian cancer in women from
2003 to 2009 in 30 provinces, as shown in Table 2. Accord-
ing to this table, during these seven years, the highest inci-
dence was in Markazi province with 6.33 in 100,000 people
in 2009 and the lowest incidence in the Kohkiloye Boyerah-
mad province in 2003 with zero reported case. This statis-
tic shows that the central, north, and north-west provinces
had the highest incidence, whereas the lowest incidence
was in the east and southeast provinces. However, statistics
show an increasing incidence in some of these provinces.
The statistical significance of changes in trend diagram of
age standardized incidence rate (ASR) of ovarian cancer
per 100 thousand people was assessed by means of WIN-
PEPI software. According to this diagram, changes in the
trend of ovarian cancer occurrence in women is significant
(Figure 2) (P = 0.048).
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Table 1. Incidence of Ovarian Cancer in Iran, According to the Statistics of Cancer Registry Center
ASR Frequency, (%) Number of Cases Statistics of Cancer Registry Center
2.34 3.51 591 2003
2.88 3.59 736 2004
2.98 3.24 793 2005
3.18 3.22 838 2006
3.96 3.46 947 2007
4.25 3.23 1096 2008
4 3.30 1077 2009
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Figure 1. Trends in the Incidence of Ovarian Cancer From 2003 to 2009
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Figure 2. Chart of Significance of Variance Trend for Occurrence of Ovarian Cancer
in Iran
5. Discussion
Ovarian cancer is the most lethal gynecologic cancer
in women and includes 25% of the genital tract neoplasms
in the United States (5, 24). Ovarian cancer is known as
the fifth leading cause of cancer death among women in
the United States (24). In Iran, it is the eighth most com-
mon cancer in terms of incidence, twelfth fatal cancer, and
sixteenth considering the burden of disease attributable
to cancer (3, 21). According to the study by Mousavi and
colleagues (3), the age-standardized incidence rate of ovar-
ian cancer in 2005 - 2006 in Iran has been reported 4.3
per 100,000 people (25); the results of this study showed
as well that the prevalence of ovarian cancer is relatively
high in Iran; the age-specific incidence rate in the current
study was 3.37 that corresponds to this study. In most de-
veloped countries, the incidence and mortality of this type
of cancer is declining, as the results of studies by Sies-
ling et al. (26) and Penault-Llorca et al. (27), conducted
in 2003 and 2006, respectively, showed that this type of
cancer has lower prevalence in developed countries, which
has been approved by the results of further studies in this
areas, such as the studies by Smith et al. and Murthy et
al. (26). These studies have shown that the incidence of
this cancer is higher in developing countries, for example,
in the study conducted in Tunisia and India, it was found
that the incidence in these countries has rapidly increased
over several years, as the annual percentage of changes
was 7.4% in Tunisia and variable from 1.8 and 6.4% in India
(4, 21, 28). The reason for this decline in developed coun-
tries versus developing countries can be the early detec-
tion with regular screening tests, such as ultrasound exam-
ination, and controlling cancer risk factors, such as obe-
sity, smoking, immobility, poor diet, early menarche, and
late menopause. According to the results of this study, the
incidence of the disease is increasing in Iran, like other
developing countries, which is consistent with the results
obtained in the studies by Almasi and Farahmand in Shi-
raz, showing a growing rate of this cancer in Iran. In
their study, the reason for this difference was reported to
be the lower use of protective factors, such as oral con-
traceptives and the lower mean age of women, compared
to the developed countries. The results of the study con-
ducted by Zendeh del and colleagues in Iran, from the
pathology centers, indicated an increasing trend in Iran,
particularly in Yazd and Isfahan provinces, which is con-
sistent with the data of cancer registry center (20). Ac-
cording to a study conducted in Semnan by Babaei and
colleagues, the age-standardized incidence of cancers of
the female genital tract increased over a 5 year period (76
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Table 2. Standardized Incidence of Ovarian Cancer in all Provinces of Iran From 2003 to 2009
Province 2009 2008 2007 2006 2005 2004 2003
East Azarbayjan 3.91 4.97 3.57 1.04 1.05 1.60 0.30
West Azarbayjan 2.78 2.16 3.23 2.25 3.68 2.88 2.37
Ardebil 4.03 2.02 1.45 3.18 0.41 3.76 0.83
Isfahan 4.36 4.45 5.01 4.16 3.11 2.72 2.27
Ilam 2.41 1.63 1.35 1.94 1.12 0.62 1.48
Bushehr 4.64 3.96 4.18 1.54 0.78 1.99 0.97
Tehran 5.70 4.52 4.29 4.25 3.76 2.96 5.80
Charmahal and Bakhtiari 1.22 3.56 4.47 3.91 2.77 0.88 0.68
South Khorasan 0.72 1.63 0.25 2.44 1.24
3.54 2.48Razavi Khorasan 3.46 3.35 3.38 2.83 1.83
North Khorasan 2.89 1.65 1.12 0.57 0.52
Khuzestan 4.32 4.56 2.99 2.02 2.17 2.70 1.10
Zanjan 2.44 1.53 1.28 0.58 0.50 1.86 0.65
Semnan 2.11 4.52 2.93 0.48 2.44 2.85 1.44
Sistan and Baluchestan 1.02 1.05 0.60 0.73 0.34 1.23 0.36
Fars 4.61 3.75 4.12 3.23 2.36 1.94 2.40
Qazvin 3.45 2.75 2.69 4.17 2.40 2.01 2.88
Qom 1.91 2.18 1.49 2.35 1.91 1.37 2.53
Golestan 3.66 4.14 3.13 2.23 3.49 2.20 2.64
Gilan 4.54 2.88 3.31 1.85 2.33 2.56 1.44
Lorestan 3.15 4.07 3.13 1.84 2.43 2.48 0.65
Mazandaran 3.01 3.77 2.38 2.82 2.19 1.64 1.82
Markazi 6.33 1.33 3.01 2.42 3.11 1.68 2.27
Hormozgan 2.41 2.61 2.77 2.77 0.82 1.16 0.30
Hamedan 3.28 4.11 3.53 2.29 1.68 1.34 1.48
Kordestan 4.25 2.52 2.09 1.91 2.46 1.62 1.11
Kerman 3.86 2.14 2.12 2.31 2.52 2.70 1.48
Kermanshah 3.96 2.97 2.53 2.37 2.00 2.06 1.85
Kohkiloye-Boyerahmad 5.36 3.84 4.47 0.80 0.93 1.83 0.00
Yazd 5.18 4.86 2.23 3.03 4.09 3.21 2.82
- 80), but the highest incidence of the disease was esti-
mated between the ages of 50 and 59 years, which is in-
consistent with the statistics of cancer registry center (70
to 80 years), which might be due to the reduced exposure
to risk factors and increased life expectancy (3, 20). Ac-
cording to Table 2, there was an increasing trend in Yazd,
Kohkiluyeh and Boyer-Ahmad, Fars, Khuzestan, North and
Razavi Khorasan, Tehran and Bushehr provinces from 2003
to 2008, while there was a downward trend in the Cha-
harmahal Bakhtiari and Qom in the incidence of ovarian
cancer. Generally, Isfahan, Tehran, Yazd, East and West
Azarbayjan had the highest incidence during this period.
As a final point, with regard to Figure 1, we can conclude
an increasing trend in the incidence of ovarian cancer that
can be due to changing patterns of risk factors, such as
lifestyle changes in the provinces and in the population,
leading to changes in the incidence of the disease. Nev-
ertheless, part of the increased incidence may be due to
higher disease diagnosis, use of different data collection
methods (population-based cancer registries since 2006),
4 Iran J Cancer Prev. 2016; 9(6):e5452.
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possible changes in diagnostic methods, raise in justifica-
tion and awareness of physicians about the importance of
reporting them and other possible causes, such as age or
the cohort effect. Therefore, more etiologic studies are rec-
ommended in these areas.
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